BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36644317)

  • 1. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma.
    Rathore M; Zhang W; Wright M; Zarei M; Vaziri-Gohar A; Hajihassani O; Abbas A; Feng H; Brody J; Markowitz SD; Winter J; Wang R
    J Cancer Sci Clin Ther; 2022; 6(4):431-445. PubMed ID: 36644317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Endothelium Promotes HER3-Mediated Cell Survival in Colorectal Cancer with Wild-Type and Mutant KRAS.
    Rathore M; Zhang W; Wright M; Bhattacharya R; Fan F; Vaziri-Gohar A; Winter J; Wang Z; Markowitz SD; Willis J; Ellis LM; Wang R
    Mol Cancer Res; 2022 Jun; 20(6):996-1008. PubMed ID: 35276002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion.
    Wang R; Bhattacharya R; Ye X; Fan F; Boulbes DR; Ellis LM
    Mol Cancer Res; 2019 Jan; 17(1):20-29. PubMed ID: 30131447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.
    Desai O; Wang R
    Oncotarget; 2023 May; 14():439-443. PubMed ID: 37163206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
    Roy-Luzarraga M; Reynolds LE; de Luxán-Delgado B; Maiques O; Wisniewski L; Newport E; Rajeeve V; Drake RJG; Gómez-Escudero J; Richards FM; Weller C; Dormann C; Meng YM; Vermeulen PB; Saur D; Sanz-Moreno V; Wong PP; Géraud C; Cutillas PR; Hodivala-Dilke K
    Cancer Res; 2022 May; 82(10):1909-1925. PubMed ID: 35350066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
    Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
    Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic landscape of endothelial cells: Key tumor microenvironment components indicating variable clinical outcomes in pancreatic ductal adenocarcinoma.
    Xie P; Tan SY; Li HF; Tang HD; Zhou JH
    Environ Toxicol; 2024 Feb; 39(2):572-582. PubMed ID: 37449672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-neuroglia interaction promotes pancreatic cancer metastasis.
    Su D; Guo X; Huang L; Ye H; Li Z; Lin L; Chen R; Zhou Q
    Theranostics; 2020; 10(11):5029-5047. PubMed ID: 32308766
    [No Abstract]   [Full Text] [Related]  

  • 9. The survival impact of palliative radiotherapy on synchronous metastatic pancreatic ductal adenocarcinoma: metastatic site can serve for radiotherapy-decision.
    Xu B; Zhou Y; Pei Q; Tan F; Zhao L; Güngör C; Wang D; Li Y; Liu W; Zhou Z
    J Cancer; 2022; 13(2):385-392. PubMed ID: 35069888
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition.
    Xiong C; Zhu Y; Xue M; Jiang Y; Zhong Y; Jiang L; Shi M; Chen H
    Aging (Albany NY); 2021 Jan; 13(3):3386-3404. PubMed ID: 33428605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
    Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
    Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
    Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
    Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature.
    Gilles ME; Maione F; Cossutta M; Carpentier G; Caruana L; Di Maria S; Houppe C; Destouches D; Shchors K; Prochasson C; Mongelard F; Lamba S; Bardelli A; Bouvet P; Couvelard A; Courty J; Giraudo E; Cascone I
    Cancer Res; 2016 Dec; 76(24):7181-7193. PubMed ID: 27754848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
    Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
    Schoeberl B; Kudla A; Masson K; Kalra A; Curley M; Finn G; Pace E; Harms B; Kim J; Kearns J; Fulgham A; Burenkova O; Grantcharova V; Yarar D; Paragas V; Fitzgerald J; Wainszelbaum M; West K; Mathews S; Nering R; Adiwijaya B; Garcia G; Kubasek B; Moyo V; Czibere A; Nielsen UB; MacBeath G
    NPJ Syst Biol Appl; 2017; 3():16034. PubMed ID: 28725482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion.
    Marimuthu S; Lakshmanan I; Muniyan S; Gautam SK; Nimmakayala RK; Rauth S; Atri P; Shah A; Bhyravbhatla N; Mallya K; Grandgenett PM; Hollingsworth MA; Datta K; Jain M; Ponnusamy MP; Batra SK
    Mol Cancer Res; 2022 Aug; 20(8):1208-1221. PubMed ID: 35533267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
    Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
    Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications.
    Yang J; Ren B; Ren J; Yang G; Fang Y; Wang X; Zhou F; You L; Zhao Y
    J Exp Clin Cancer Res; 2023 Jun; 42(1):155. PubMed ID: 37370109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis.
    Wang Y; Guo H; Zhang Z; Wang Q; Tian X; Yang Y
    Ann Transl Med; 2021 Apr; 9(7):557. PubMed ID: 33987255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.